HealthTree Myeloma Community

Donate

person Sign In / Create Account

Myeloma News

Breaking Headlines

Aug. 16, 2022

How is Frailty Defined in Multiple Myeloma?

Aug. 15, 2022

Myeloma Round Table: Developing a Treatment Strategy — Chicago, April 30, 2022 (Part 2)

Aug. 15, 2022

Why I Chose a Myeloma CAR T Clinical Trial at Relapse

Aug. 15, 2022

Capitalizing Life Insurance to Pay for Care

Aug. 12, 2022

Understanding the Difference Between Chemo and Immunotherapies in Myeloma with Dr. Scott Goldsmith

Aug. 11, 2022

Salt Lake City Myeloma Round Table

Aug. 11, 2022

Cancer Buddies and Coaching

Aug. 11, 2022

Journaling Your Myeloma Story Can Improve Your Health

Aug. 10, 2022

Myeloma Round Table: Essential Information for Newly Diagnosed Patients — Chicago, April 30, 2022 (Part 1)

Aug. 09, 2022

FDA Grants Breakthrough Therapy Designation to Talquetamab for Multiple Myeloma

Aug. 09, 2022

Building Your HealthCare Team

Aug. 09, 2022

HealthTree Foundation Launches New Journaling Feature for Multiple Myeloma Patients

Recent Articles

Myeloma Round Table: Treating Relapsed/Refractory Disease at MD Anderson — Houston, March 26, 2022 (Part 2)

August 8, 2022

Dr. Patel, Dr. Lee, and NP Rebecca Lu explain the considerations they keep in mind when treating relapsed/refractory disease at MD Anderson.

Comparing Black vs. White Myeloma Patient Outcomes

August 8, 2022

How do black vs. white myeloma patients do if given the same care? This OSU study shares outcomes for patients under 50.

Join Us In Person or Online for the Buffalo Myeloma Round Table on September 17

August 6, 2022

Join us in-person or online and learn from top myeloma experts in the Buffalo Myeloma Round Table on September 17, 2022

Balance Part 2: Where to Start and How to Improve

August 4, 2022

Core stability, strength and balance are key for myeloma patients to prevent falls and injury.

Myeloma Round Table: Precursors Through First Treatment — Houston, March 26, 2022 (Part 1)

August 4, 2022

Drs. Orlowski and Qazilbash discuss how precursor conditions and transplants are assessed at MD Anderson as well as what the future may bring.

New in Myeloma

FDA Grants Breakthrough Therapy Designation to Talquetamab for Multiple Myeloma

An Additional Update for Oncopeptides’ Pepaxto (Melflufen)

European Medicines Agency Beats FDA to the Punch with Conditional Approval of Teclistamab for Multiple Myeloma

Who Responds Best to the Multiple Myeloma BCMA Bispecific Antibodies?

Three Genes That Indicate a Potential Response to Selinexor Myeloma Therapy

A New Revision to the Revised Myeloma Staging System?

Life With Myeloma

Why I Chose a Myeloma CAR T Clinical Trial at Relapse

Capitalizing Life Insurance to Pay for Care

Cancer Buddies and Coaching

Journaling Your Myeloma Story Can Improve Your Health

Comparing Black vs. White Myeloma Patient Outcomes

Balance Part 2: Where to Start and How to Improve

Myeloma Basics

How is Frailty Defined in Multiple Myeloma?

Understanding the Difference Between Chemo and Immunotherapies in Myeloma with Dr. Scott Goldsmith

Building Your HealthCare Team

How Long Will CAR-T Cell Therapy Last?

How Do CAR-T Cells Kill Myeloma?

The Difference Between 1Q Gain and 1Q Amplification in Multiple Myeloma

HealthTree

Myeloma Round Table: Developing a Treatment Strategy — Chicago, April 30, 2022 (Part 2)

Salt Lake City Myeloma Round Table

Myeloma Round Table: Essential Information for Newly Diagnosed Patients — Chicago, April 30, 2022 (Part 1)

Myeloma Round Table: Treating Relapsed/Refractory Disease at MD Anderson — Houston, March 26, 2022 (Part 2)

Myeloma Round Table: Precursors Through First Treatment — Houston, March 26, 2022 (Part 1)

Full Show: Mid-Year Myeloma Update with Paul Richardson, MD, Dana Farber Cancer Institute

Clinical Trials

The FDA Expanded Access Program for Multiple Myeloma and Early Access for Teclistamab

Clinical Trial: Can Yoga Help Alleviate Peripheral Neuropathy After Chemo?

ASH 2021: Key Trial Confirms Impact of Daratumumab

Clinical Trial: A New Myeloma Therapy Tasquinimod Targeting MDSCs

Clinical Trial: A Personalized Vaccine in Smoldering Myeloma at MD Anderson Cancer Center

Clinical Trials: Venetoclax for Multiple Myeloma 11;14 Translocation Patients

Research

Gaps in Optimized Genetic and Imaging Testing for Myeloma Patients

The Dawning Era of Bispecific Antibodies in Myeloma

Watching Your Free Light Chain Ratio to Determine Smoldering Myeloma Progression to Active Myeloma

A Meeting of the Myeloma Minds in Vienna

Myeloma-Related Distress During COVID

Real-World Data on CAR T-Cell Therapy in Multiple Myeloma

HealthTree Press

HealthTree Foundation Launches New Journaling Feature for Multiple Myeloma Patients

Myeloma Crowd Changes Its Name to HealthTree Foundation for Multiple Myeloma

Cure Today: Teaching Others Through Cancer Advocacy

Cancer Today: Crowdsourcing Support

HealthTree Foundation for Multiple Myeloma Wins GSK's First Target the Future Think Tank Challenge

HealthTree Coach in the News

Thanks to our HealthTree Community for Myeloma Sponsors:

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

Breaking Headlines

Recent Articles

New in Myeloma

Life With Myeloma

Myeloma Basics

HealthTree

Clinical Trials

Research

HealthTree Press

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Thanks to our HealthTree Community for Myeloma Sponsors:

Follow Us